Nutraveris
Thursday, February 14, 2019
Category : NEWS, INGREDIENTS, CLINICAL EVIDENCE | Author : experts | Comment : No Comments
Tags:

NOL, Nutraveris Online, the most efficient data solution to create, keep up-to-date and launch your products in the 28 EU member states, used for 10years by more than 500 industry leaders informs you:

 

Vitamin C is a strong antioxidant. The authors of this study wished to determine whether this antioxidant capacity can help to prevent exercise-induced muscle damage. 19 healthy women have been recruited for this randomized, double-blinded and placebo-controlled trial which used a crossover design including a 1-week washout period.

They performed 30 min moderate intensity cycling after ingesting 1 g vitamin C or placebo.

Vitamin C

Vitamin C prevented the increases in plasma albumin and total protein levels, and the reduction in glucose observed after placebo (p = 0.001). Superoxide dismutase was increased after placebo but not after vitamin C (p = 0.002), whereas malondialdehyde decreased only after the vitamin C supplementation (p < 0.05). Slight muscle damage have been noted in both groups after exercise, without differences between groups.

 

Therefore, vitamin C possesses antioxidant effects during exercise, but does not prevent muscle damage.

 

Yimcharoen M, Kittikunnathum S, Suknikorn C, Nak-On W, Yeethong P, Anthony TG, Bunpo P. Effects of ascorbic acid supplementation on oxidative stress markers in healthy women following a single bout of exercise. J Int Soc Sports Nutr. 2019 Jan 21;16(1):2.

 

This information has been sourced by NOL, a collaborative and complete tool which contains all Regulatory, Scientific and Marketing data

  • It solves all regulatory issues since it contains the required information on all ingredients authorized in the 28 European member states…on regulatory status, health claims, authority opinions
  • It protects your investments since it is updated in real time with reliable quality information analyzed and reviewed by our experts, available hotline.
  • It enables you to be the most responsive with monthly reports and live alerts and a personal use of the information with a report editing tool and customizable bookmarks.

With NOL let’s : 

  • Formulate new innovative products
  • Check if your already existing formulas are still compliant with the in force regulations
  • Adapt your existing formulas to the requirements of other European countries where you are willing to export them
  • Do scientific & regulatory & marketing monitoring which enable to anticipate the withdrawal of products, the safety issues, new interesting scientific studies, the arrival of new players on the market…

 

More information on www.nutraveris.com

Contact our Scientific & Regulatory experts at NUTRAVERIS

contact@nutraveris.com, +33 2 96 76 54 87

Tuesday, February 12, 2019
Category : NEWS, INGREDIENTS, REGULATORY | Author : experts | Comment : No Comments
Tags:

NOL, Nutraveris Online, the most efficient data solution to create, keep up-to-date and launch your products in the 28 EU member states, used for 10 years by more than 500 industry leaders informs you:

The Novel food Catalogue entries for Cannabis sativa L. and Cannabidiol / Cannabinoids have been updated in January 2019 and now indicate that :

  • “Some products derived from the Cannabis sativa plant or plant parts such as seeds, seed oil, hemp seed flour, defatted hemp seed have a history of consumption in the EU and therefore, are not novel. Other specific national legislation may restrict the placing on the market of this product as a food or food ingredient in some Member States.” Only ingredients derived from hemp seed are now cited as having a history of consumption in the EU.
  • “Extracts of Cannabis sativa L. and derived products containing cannabinoids are considered novel foods as a history of consumption has not been demonstrated. This applies to both the extracts themselves and any products to which they are added as an ingredient (such as hemp seed oil). This also applies to extracts of other plants containing cannabinoids. Synthetically obtained cannabinoids are considered as novel.”

This modification clarifies that the European Authorities consider that it is forbidden to market food or food supplements containing cannabidiol in all the European Union (considered as novel according to Regulation (EU) 2015/2283). For information a novel food application for trans-cannabidiol (for a use in food supplements) is under assessment by EFSA and the opinion is expected to be published in March 2019.

 

Cannabis sativa

 

For example in UK where some cannabidiol products were already marketed because of an unclear legal context, it is now indicated on the website of the FSA: There has been a recent change to the EU Novel Food Catalogue which affects some cannabidiol (CBD) products. Food businesses have not been able to show there was a significant history of consumption of these products in food and food supplements prior to May 1997 in the EU. The FSA are considering the way forward in light of this clarification at EU level (meeting with relevant industry representative bodies, local authorities and other stakeholders to clarify how to achieve compliance in the marketplace in a proportionate manner).

 

This information has been sourced by NOL, a collaborative and complete tool which contains all Regulatory, Scientific and Marketing data

  • It solves all regulatory issues since it contains the required information on all ingredients authorized in the 28 European member states…on regulatory status, health claims, authority opinions
  • It protects your investments since it is updated in real time with reliable quality information analyzed and reviewed by our experts, available hotline.
  • It enables you to be the most responsive with monthly reports and live alerts and a personal use of the information with a report editing tool and customizable bookmarks.

With NOL let’s : 

  • Formulate new innovative products
  • Check if your already existing formulas are still compliant with the in force regulations
  • Adapt your existing formulas to the requirements of other European countries where you are willing to export them
  • Do scientific & regulatory & marketing monitoring which enable to anticipate the withdrawal of products, the safety issues, new interesting scientific studies, the arrival of new players on the market…

 

More information on www.nutraveris.com

Contact our Scientific & Regulatory experts at NUTRAVERIS

contact@nutraveris.com, +33 2 96 76 54 87

Thursday, February 7, 2019
Category : NEWS, INGREDIENTS, INNOVATION, CLINICAL EVIDENCE | Author : experts | Comment : No Comments
Tags:

NOL, Nutraveris Online, the most efficient data solution to create, keep up-to-date and launch your products in the 28 EU member states, used for 10years by more than 500 industry leaders informs you:

The effects of alpha lipoid acid (ALA) on plasma lipids remains unclear due to contradictory results obtained in clinical trials. To clarify the effects of ALA, this meta-analysis includes 12 randomized and controlled trials assessing the effects of ALA on lipid profile.

 

alpha lipoic acid

 

Results show that ALA reduces total cholesterol level in comparison to controls (Weight mean difference = -10.18 mg/dL, 95% CI: -16.16, -4.20 mg/dL, p = 0.001). A significant reduction in LDL-cholesterol has also been measured (WMD = -9.22 mg/dL, 95% CI: -18.28, -0.16 mg/dL, p = 0.001). However, no change in HDL-cholesterol has been measured. Regarding triglycerides, the analysis show no significant effect of ALA on triglycerides, except in a subgroup analysis based in health status (diabetic vs. diabetic) in which triglycerides were reduced in both populations.

 

Therefore, ALA reduce plasma lipids. However, the consequences of these changes has to be clarified, notably regarding cardiovascular diseases.

 

Haghighatdoost F, Hariri M. Does alpha-lipoic acid affect lipid profile? A meta-analysis and systematic review on randomized controlled trials. Eur J Pharmacol. 2019 Jan 8. pii: S0014-2999(19)30009-3.

 

This information has been sourced by NOL, a collaborative and complete tool which contains all Regulatory, Scientific and Marketing data

  • It solves all regulatory issues since it contains the required information on all ingredients authorized in the 28 European member states…on regulatory status, health claims, authority opinions
  • It protects your investments since it is updated in real time with reliable quality information analyzed and reviewed by our experts, available hotline.
  • It enables you to be the most responsive with monthly reports and live alerts and a personal use of the information with a report editing tool and customizable bookmarks.

With NOL let’s : 

  • Formulate new innovative products
  • Check if your already existing formulas are still compliant with the in force regulations
  • Adapt your existing formulas to the requirements of other European countries where you are willing to export them
  • Do scientific & regulatory & marketing monitoring which enable to anticipate the withdrawal of products, the safety issues, new interesting scientific studies, the arrival of new players on the market…

 

More information on www.nutraveris.com

Contact our Scientific & Regulatory experts at NUTRAVERIS

contact@nutraveris.com, +33 2 96 76 54 87

Tuesday, February 5, 2019
Category : NEWS, REGULATORY | Author : experts | Comment : No Comments
Tags:

NOL, Nutraveris Online, the most efficient data solution to create, keep up-to-date and launch your products in the 28 EU member states, used for 10years by more than 500 industry leaders informs you:

 

In 2019, the European elections will take place between 23 and 26 May 2019 to elect the MEPs representing the Member States of the European Union, and the European Commission will change at the end of 2019.

European changes in 2019

Concerning the Brexit (departure of the United Kingdom from the European Union) the discussions at European level on a draft Withdrawal Agreement are still ongoing. Two main scenarios are still possible:

  • the Withdrawal Agreement is ratified before 30 March 2019: in this case, European Union law would continue to apply in the United Kingdom until 31 December 2020 (transition period).
  • or the Withdrawal Agreement is not ratified by 30 March 2019: this is the “no deal” scenario, implying that EU law will no longer apply in the UK from 30 March 2019.
    We invite you to follow further discussions on this topic by 30 March 2019.

According to information from the UK authorities, the main safety principles of European food law will be converted into UK law. However adaptations will be needed, particularly:

  • The UK would no longer fall within the scope of the mutual recognition principle.
  • Concerning the mandatory labelling of food, changes will be necessary for the address:

For pre-packed products sold in the UK, the label would need to include the name and a UK address of the responsible food business operator. The food business operator is the business under whose name the food is marketed in the UK or, if that operator is not established in the UK, the importer of the product into the UK. An EU address alone would no longer be valid for the UK market.

Similarly, a UK address alone would no longer be valid for the EU market and an address within the remaining EU member states will be required following EU exit.

A UK address together with an EU address on the label would mean that the label is valid for both the UK and EU markets.

 

This information has been sourced by NOL, a collaborative and complete tool which contains all Regulatory, Scientific and Marketing data

  • It solves all regulatory issues since it contains the required information on all ingredients authorized in the 28 European member states…on regulatory status, health claims, authority opinions
  • It protects your investments since it is updated in real time with reliable quality information analyzed and reviewed by our experts, available hotline.
  • It enables you to be the most responsive with monthly reports and live alerts and a personal use of the information with a report editing tool and customizable bookmarks.

With NOL let’s : 

  • Formulate new innovative products
  • Check if your already existing formulas are still compliant with the in force regulations
  • Adapt your existing formulas to the requirements of other European countries where you are willing to export them
  • Do scientific & regulatory & marketing monitoring which enable to anticipate the withdrawal of products, the safety issues, new interesting scientific studies, the arrival of new players on the market…

 

More information on www.nutraveris.com

Contact our Scientific & Regulatory experts at NUTRAVERIS

contact@nutraveris.com, +33 2 96 76 54 87

Thursday, January 31, 2019
Category : NEWS, INGREDIENTS, INNOVATION, CLINICAL EVIDENCE | Author : experts | Comment : No Comments
Tags:

NOL, Nutraveris Online, the most efficient data solution to create, keep up-to-date and launch your products in the 28 EU member states, used for 10years by more than 500 industry leaders informs you:

 

The aim of this observational study was to analyze the association between retinoid intake (total vitamin A, retinol, β-carotene, α-carotene, β-cryptoxanthin, lycopene, as wellas lutein and zeaxanthin) and self-reported gastrointestinal symptoms (daily number of bowel movements, and the presence of painful tenesmus, flatulence, and constipation) in Caucasian individuals in the remission phase of  ulcerative colitis.

To do so, 56 ulcerative colitis remission individuals were recruited and retinoid intakes were analyzed on the basis of three-day dietary records.

 

Box plots of lutein and zeaxanthin intake

Box plots of lutein and zeaxanthin intake in groups of individuals stratified by the analyzed symptoms of tenesmus, flatulence and constipation. (-) symptom not declared; (+) symptom declared.

 

Results showed that one in every seven individuals reported recurring constipation. Higher intake of lutein and zeaxanthin may lower the incidence of constipation (p = 0.013).

Authors concluded that the intake of retinoids other than lutein and zeaxanthin was not associated with the incidence of constipation or other gastrointestinal symptoms.

 

Głąbska D, Guzek D, Zakrzewska P, Lech G. Intake of Lutein and Zeaxanthin as a Possible Factor Influencing Gastrointestinal Symptoms in Caucasian Individuals with Ulcerative Colitis in Remission Phase. J Clin Med. 2019 Jan 11;8(1). pii: E77.

 

This information has been sourced by NOL, a collaborative and complete tool which contains all Regulatory, Scientific and Marketing data

  • It solves all regulatory issues since it contains the required information on all ingredients authorized in the 28 European member states…on regulatory status, health claims, authority opinions
  • It protects your investments since it is updated in real time with reliable quality information analyzed and reviewed by our experts, available hotline.
  • It enables you to be the most responsive with monthly reports and live alerts and a personal use of the information with a report editing tool and customizable bookmarks.

With NOL let’s : 

  • Formulate new innovative products
  • Check if your already existing formulas are still compliant with the in force regulations
  • Adapt your existing formulas to the requirements of other European countries where you are willing to export them
  • Do scientific & regulatory & marketing monitoring which enable to anticipate the withdrawal of products, the safety issues, new interesting scientific studies, the arrival of new players on the market…

 

More information on www.nutraveris.com

Contact our Scientific & Regulatory experts at NUTRAVERIS

contact@nutraveris.com, +33 2 96 76 54 87